Turin, Italy, 31 March 2022 – Data support the use of Kither Biotech’s lead asset, KIT2014, in obstructive airway diseases…
Read MorePress releases
Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
Turin, Italy, 16 March 2022 – Kither Biotech (“Kither” or “the Company”), a biopharmaceutical company developing novel therapies for rare…
Read MoreKither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases
Turin, Italy, 5 July 2019 – Kither Biotech raises a €5.6m financing round to support the clinical development of a…
Read More